 - Re-enrollment of a subject that has discontinued the study as a pre-treatment screen failure i.e. a consented patient who did not receive avelumab is permitted. If re-enrolled, the subject must be re-consented. Only the screening procedures performed outside of protocol-specified timing must be repeated. 